• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Myomo Inc. (Amendment)

    4/25/24 7:13:03 PM ET
    $MYO
    Industrial Specialties
    Health Care
    Get the next $MYO alert in real time by email
    SC 13G/A 1 rosalind_myo_13ga4_apr25.htm Schedule 13G

     


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G/A

    (Amendment No. 4)

     

    Under the Securities Exchange Act of 1934

    Myomo, Inc.

    (Name of Issuer)

    Common Shares

    (Title of Class of Securities)

    62857J201

    (CUSIP Number)

    March 31, 2024

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ¨  Rule 13d-1(b)
    x  Rule 13d-1(c)
    ¨  Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


     

    NYC#: 139632.2


     


     

     

     

     

     

     

    CUSIP No. 62857J201

     

    13G/A

     

    Page 2 of 8 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Rosalind Advisors, Inc.

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    ONTARIO, CANADA

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5.

     

    SOLE VOTING POWER  
     
    0

     

    6.

     

    SHARED VOTING POWER
     
    2,447,740 shares of Common Stock

    4,575,385 shares of Common Stock issuable upon exercise of pre-funded warrants

     

    7.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    8.

     

    SHARED DISPOSITIVE POWER
     
    2,447,740 shares of Common Stock

    4,575,385 shares of Common Stock issuable upon exercise of pre-funded warrants

     

     

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,447,740 shares of Common Stock

    4,575,385 shares of Common Stock issuable upon exercise of pre-funded warrants

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.9% above1

     

     

    12.

     

    TYPE OF REPORTING PERSON (see instructions)

    CO

     

     

     

     

     

     

     


    1 The percentage set forth in Row 11 of the cover page for each Reporting Person is based upon 28,487,168 shares of the Issuer’s common stock outstanding as of March 1, 2024, in accordance with Issuer’s 10-K filed on March 8, 2024. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon exercise of such reported securities and do not give effect to blocker provisions. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

      


     

    NYC#: 139632.2


     


    CUSIP No. 62857J201

     

    13G/A

     

    Page 3 of 8 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Steven Salamon

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    ONTARIO, CANADA

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5.

     

    SOLE VOTING POWER
     
    0

     

    6.

     

    SHARED VOTING POWER
     
    2,447,740 shares of Common Stock

     4,575,385 shares of Common Stock issuable upon exercise of pre-funded warrants

     

    7.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    8.

     

    SHARED DISPOSITIVE POWER
     
    2,447,740 shares of Common Stock

     4,575,385 shares of Common Stock issuable upon exercise of pre-funded warrants

     

     

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,447,740 shares of Common Stock

     4,575,385 shares of Common Stock issuable upon exercise of pre-funded warrants

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.9% above

     

     

    12.

     

    TYPE OF REPORTING PERSON (see instructions)

    IN

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Gil Aharon

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    ONTARIO, CANADA

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5.

     

    SOLE VOTING POWER
     
    0

     

    6.

     

    SHARED VOTING POWER
     
     2,447,740 shares of Common Stock

     4,575,385 shares of Common Stock issuable upon exercise of pre-funded warrants

     

    7.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    8.

     

    SHARED DISPOSITIVE POWER
     
     2,447,740 shares of Common Stock

     4,575,385 shares of Common Stock issuable upon exercise of pre-funded warrants

     

     

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     2,447,740 shares of Common Stock

     4,575,385 shares of Common Stock issuable upon exercise of pre-funded warrants

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.9% above

     

     

    12.

     

    TYPE OF REPORTING PERSON (see instructions)

    IN

     

     

     

     

     

     

     

     

    CUSIP No. 62857J201

     

    13G/A

     

    Page 4 of 8 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Rosalind Master Fund L.P.

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    CAYMAN ISLANDS

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5.

     

    SOLE VOTING POWER
     
    0

     

    6.

     

    SHARED VOTING POWER
     
    2,447,740 shares of Common Stock

     4,575,385 shares of Common Stock issuable upon exercise of pre-funded warrants

     

    7.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    8.

     

    SHARED DISPOSITIVE POWER
     
    2,447,740 shares of Common Stock

     4,575,385 shares of Common Stock issuable upon exercise of pre-funded warrants

     

     

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,447,740 shares of Common Stock

     4,575,385 shares of Common Stock issuable upon exercise of pre-funded warrants

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.9% above

     

     

    12.

     

    TYPE OF REPORTING PERSON (see instructions)

    PN

     

     

     

     

     

     

     

     

     

     

     

     


     

    NYC#: 139632.2


     


     

     

     

     

     

     

    CUSIP No. 62857J201

     

    13G/A

     

    Page 5 of 8 Pages

     

     

     

     

     

    Item 1.

     

    (a)

    Name of Issuer: Myomo, Inc.

     

     

     

     

    (b)

    Address of Issuer’s Principal Executive Offices
    137 Portland St., 4th Floor, Boston, Massachusetts

     

     

     

    Item 2.

     

    (a)

    Name of Person Filing

    Rosalind Advisors, Inc. (“Advisor” to RMF)

    Rosalind Master Fund L.P. (“RMF”)

    Steven Salamon (“President”)

    Steven Salamon is the portfolio manager of the Advisor which advises RMF.

     

     

     

     

    (b)

    Address of the Principal Office or, if none, residence
    Rosalind Advisors, Inc.

    15 Wellesley Street West,

    Suite 326

    Toronto, Ontario

    M4Y 0G7 Canada

     

    Rosalind Master Fund L.P.

    P.O. Box 309

    Ugland House, Grand Cayman

    KY1-1104, Cayman Islands

     

    Steven Salamon

    15 Wellesley Street West,

    Suite 326

    Toronto, Ontario

    M4Y 0G7 Canada

     

    Gilad Aharon

    15 Wellesley Street West,

    Suite 326

    Toronto, Ontario

    M4Y 0G7 Canada

     

     

     

     

     

    (c)

    Citizenship
    Rosalind Advisors, Inc.: Ontario, Canada

    Rosalind Master Fund L.P.: Cayman Islands

    Steven Salamon: Ontario, Canada

    Gilad Aharon: Ontario, Canada

     

     

     

     

    (d)

    Title of Class of Securities
    Common Stock

     

     

     

     

    (e)

    CUSIP Number
    62857J201


     

    NYC#: 139632.2


     


     

     

     

     

     

    CUSIP No. 62857J201

     

    13G/A

     

    Page 6 of 8 Pages

     

     

     

     

     

    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)

    ¨

    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

     

     

     

     

    (b)

    ¨

    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

     

     

     

     

    (c)

    ¨

    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

     

     

     

     

    (d)

    ¨

    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

     

     

     

     

    (e)

    ¨

    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

     

     

     

     

    (f)

    ¨

    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

     

     

     

     

    (g)

    ¨

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

     

     

     

     

    (h)

    ¨

    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

     

     

     

     

    (i)

    ¨

    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

     

     

     

     

    (j)

    ¨

    Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

     

     

    Item 4.  Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

     

     

     

     

     

    (a)

     

    Amount beneficially owned:  

     

    The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 12 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.  The percentage set forth in Row 11 of the cover page for each Reporting Person is based upon 26,516,203 shares of the Issuer’s common stock outstanding as of November 02, 2023, in accordance with Issuer’s 10-Q filed on November 07, 2023.

    Rosalind Master Fund L.P. may have been deemed to have the beneficial ownership of 2,447,740 shares of common stock representing the beneficial ownership of approximately 9.2% of the common stocks as mentioned above, which excludes the 4,575,385 shares issuable upon the exercise of pre-funded warrants because they contain a blocker provision under which the holder thereof does not have the right to exercise any of the warrant to the extent that such exercise would result in beneficial ownership by the holder in excess of 9.99% of the Common Stock. Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able to exercise any of the warrants due to the Blockers.

    Rosalind Advisors, Inc. is the investment advisor to RMF and may be deemed to be the beneficial owner of shares held by RMF.  Steven Salamon is the portfolio manager of the Advisor and may be deemed to be the beneficial owner of shares held by RMF.  Notwithstanding the foregoing, the Advisor and Mr. Salamon disclaim beneficial ownership of the shares.

     

     

     

     

     

     

    (b)

     

    Percent of class:  

    Rosalind Advisors, Inc. – 9.9% above

    Rosalind Master Fund L.P. – 9.9% above

    Steven Salamon – 9.9% above

    Gilad Aharon – 9.9% above

     

     

     

     

     

     


     

    NYC#: 139632.2


     


     

     

     

     

     

    CUSIP No. 62857J201

     

    13G/A

     

    Page 7 of 8 Pages

     

     

     

     

     

     

    (c)

     

    Number of shares as to which the person has:  

     

     

     

    (i)

    Shared power to vote or to direct the vote  

    Rosalind Advisors, Inc. –  2,447,740 shares of Common Stock

    Rosalind Master Fund L.P. –  2,447,740 shares of Common Stock

    Steven Salamon – 2,447,740 shares of Common Stock

    Gilad Aharon - 2,447,740 shares of Common Stock

     

     

     

     

     

     

     

     

     

    (ii)

    Sole power to dispose or to direct the disposition of  – 0

     

     

     

     

     

     

     

     

    (iii)

    Shared power to dispose or to direct the disposition of  

    Rosalind Advisors, Inc. –  2,447,740 shares of Common Stock

    Rosalind Master Fund L.P. – 2,447,740 shares of Common Stock

    Steven Salamon –  2,447,740 shares of Common Stock

    Gilad Aharon - 2,447,740 shares of Common Stock

     

     

     

     

     

     

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

    Item 5.  Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following     o.

    Instruction. Dissolution of a group requires a response to this item.

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

    Item 7 – 9.  Not Applicable


     

    NYC#: 139632.2


     


     

     

     

     

     

    CUSIP No. 62857J201

     

    13G/A

     

    Page 8 of 8 Pages

     

     

     

     

     

    Item 10.  Certification.

     

     

     

     

     

     

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

     

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    04/25/2024

    Date

     

     

    Signature

     

    Steven Salamon/President Rosalind Advisors, Inc.

    Name/Title

     

     

    Exhibit A

    Joint Filing Agreement

     

    The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial ownership of shares of Common Stock of Myomo, Inc. is filed jointly, on behalf of each of them.

     

     

    Rosalind Advisors, Inc.

    By: _____________________________

    Name: Steven Salamon

    Title: President

     

    Rosalind Master Fund L.P.

    By: _____________________________

    Name: Mike McDonald

    Title: Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)

     

    By: _____________________________

    Name: Steven Salamon


     

    NYC#: 139632.2

    Get the next $MYO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MYO

    DatePrice TargetRatingAnalyst
    7/31/2024$7.00Buy
    Craig Hallum
    5/20/2024$7.00Buy
    Lake Street
    12/15/2023$6.50Buy
    H.C. Wainwright
    More analyst ratings

    $MYO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Myomo Announces Participation in Upcoming Investor Conferences

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced its participation in two upcoming investor conferences. On May 20, Myomo's President and Chief Executive Officer Paul Gudonis and Chief Financial Officer David Henry will participate virtually in a fireside chat as part of Alliance Global Partners Annual Healthcare Company Showcase. The fireside chat will begin at 11:20 a.m ET. The registration link for the conference can be found here. Chief Financial Officer David Henry will present at Sidoti's Virtual Micro Cap Conference

    5/14/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo Appoints Joseph M. Manko to its Board of Directors

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Joseph M. ("Joe") Manko Jr. as a director effective May 9, 2026, to serve until the 2027 annual meeting of stockholders. With this appointment, Myomo has seven directors. Mr. Manko is an accomplished investor with over 25 years of experience in investment banking, private equity, asset management and corporate strategy. Mr. Manko is currently the Senior Principal of Horton Capital Management LLC ("The Horton Fund"), a significant shareholder in the Company. Mr.

    5/13/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo Reports First Quarter 2026 Financial and Operating Results

    Revenue of $10.1 million with 49% of first quarter revenue from recurring patient sources MyoPro® orders received during the quarter were up 12% year-over-year Expanded gross margin, lower operating expenses and narrowed net loss Conference call begins at 4:30pm Eastern time today Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2026. "Earlier this year we established four success pillars for 2026, including growing revenue from recurring patient sources, increasing

    5/7/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kirk Thomas F bought $24,825 worth of shares (25,000 units at $0.99), increasing direct ownership by 4% to 653,863 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    6/1/26 8:23:56 AM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Kirk Thomas F bought $68,243 worth of shares (75,006 units at $0.91), increasing direct ownership by 14% to 628,863 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    5/18/26 8:20:32 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Manko Joseph M. Jr. bought $173,908 worth of MYO (201,197 units at $0.86) (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    5/18/26 4:59:21 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kirk Thomas F bought $24,825 worth of shares (25,000 units at $0.99), increasing direct ownership by 4% to 653,863 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    6/1/26 8:23:56 AM ET
    $MYO
    Industrial Specialties
    Health Care

    Chief Medical Officer Kovelman Harry sold $32,239 worth of shares (32,000 units at $1.01), decreasing direct ownership by 23% to 108,618 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    5/28/26 9:53:08 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Kirk Thomas F bought $68,243 worth of shares (75,006 units at $0.91), increasing direct ownership by 14% to 628,863 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    5/18/26 8:20:32 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Myomo with a new price target

    Craig Hallum initiated coverage of Myomo with a rating of Buy and set a new price target of $7.00

    7/31/24 7:20:07 AM ET
    $MYO
    Industrial Specialties
    Health Care

    Lake Street initiated coverage on Myomo with a new price target

    Lake Street initiated coverage of Myomo with a rating of Buy and set a new price target of $7.00

    5/20/24 9:00:38 AM ET
    $MYO
    Industrial Specialties
    Health Care

    H.C. Wainwright initiated coverage on Myomo with a new price target

    H.C. Wainwright initiated coverage of Myomo with a rating of Buy and set a new price target of $6.50

    12/15/23 8:26:14 AM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    SEC Filings

    View All

    SEC Form SD filed by Myomo Inc.

    SD - MYOMO, INC. (0001369290) (Filer)

    5/28/26 4:23:53 PM ET
    $MYO
    Industrial Specialties
    Health Care

    SEC Form DEFA14A filed by Myomo Inc.

    DEFA14A - MYOMO, INC. (0001369290) (Filer)

    5/14/26 4:10:02 PM ET
    $MYO
    Industrial Specialties
    Health Care

    SEC Form DEF 14A filed by Myomo Inc.

    DEF 14A - MYOMO, INC. (0001369290) (Filer)

    5/14/26 4:05:31 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Leadership Updates

    Live Leadership Updates

    View All

    Myomo Appoints Joseph M. Manko to its Board of Directors

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Joseph M. ("Joe") Manko Jr. as a director effective May 9, 2026, to serve until the 2027 annual meeting of stockholders. With this appointment, Myomo has seven directors. Mr. Manko is an accomplished investor with over 25 years of experience in investment banking, private equity, asset management and corporate strategy. Mr. Manko is currently the Senior Principal of Horton Capital Management LLC ("The Horton Fund"), a significant shareholder in the Company. Mr.

    5/13/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo Appoints William J Febbo to its Board of Directors

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of William "Will" Febbo as a director effective April 14, 2026, to serve until the 2028 annual meeting of stockholders. With this appointment, Myomo has six directors. Mr. Febbo is an accomplished executive, entrepreneur, and investor with over 30 years of experience in healthcare, financial services, and technology-driven businesses. He has successfully guided organizations through substantial growth, strategic transformations and acquisitions, and significant ca

    4/16/26 4:05:00 PM ET
    $MYO
    $OPRX
    Industrial Specialties
    Health Care
    Real Estate

    Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a

    2/3/25 4:00:00 PM ET
    $INGN
    $MDT
    $MYO
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $MYO
    Financials

    Live finance-specific insights

    View All

    Myomo Reports First Quarter 2026 Financial and Operating Results

    Revenue of $10.1 million with 49% of first quarter revenue from recurring patient sources MyoPro® orders received during the quarter were up 12% year-over-year Expanded gross margin, lower operating expenses and narrowed net loss Conference call begins at 4:30pm Eastern time today Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2026. "Earlier this year we established four success pillars for 2026, including growing revenue from recurring patient sources, increasing

    5/7/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo to Report First Quarter 2026 Financial Results on May 7

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2026 on Thursday, May 7, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after the call star

    5/1/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    Fourth quarter revenue of $11.4 million, full year revenue of $40.9 million 42% of fourth quarter revenue from recurring patient sources Record 241 authorizations and orders in the quarter Introduces 2026 revenue guidance of $43 million to $46 million as Company emphasizes recurring sources of revenue Conference call begins today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2025. "We delivered 2025 revenue at the midpoint of o

    3/9/26 4:06:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Myomo Inc.

    SC 13G/A - MYOMO, INC. (0001369290) (Subject)

    10/18/24 2:21:35 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Myomo Inc.

    SC 13G/A - MYOMO, INC. (0001369290) (Subject)

    7/12/24 10:35:49 AM ET
    $MYO
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Myomo Inc.

    SC 13G/A - MYOMO, INC. (0001369290) (Subject)

    7/11/24 6:02:07 PM ET
    $MYO
    Industrial Specialties
    Health Care